证券代码：600479 证券简称：千金药业 公告编号：2025-041 株洲千金药业股份有限公司 关于发行股份及支付现金购买资产暨关联交易报告书（草案） （上会稿）修订说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 株洲千金药业股份有限公司（以下简称"公司"）拟通过发行股份及支付现 金方式购买湖南千金湘江药业股份有限公司 28.92%的股权及湖南千金协力药业 有限公司 68.00%的股权（以下简称"本次交易"）。 公司于 2025 年 8 月 6 日收到上海证券交易所出具的《关于株洲千金药业 股份有限公司发行股份及支付现金购买资产暨关联交易申请的审核中心意见落 实函》(上证上审(2025)60 号)(以下简称"《审核中心意见落实函》")。根据《审 核中心意见落实函》及上海证券交易所审核意见的要求，公司于 2025 年 8 月 8 日披露了《株洲千金药业股份有限公司发行股份及支付现金购买资产暨关联交易 报告书（草案）（上会稿）》(以下简称"草案(上会稿)")等文件。具体内容详见 公司刊登在上海证券交易所网站（h ...

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

Group 1 - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. for approximately 55.85 million yuan, enhancing its global supply chain and competitiveness in the reagent field [1] - Qianjin Pharmaceutical has received registration certificates for two drugs, enriching its product line and strengthening its position in the treatment of vitamin B12 deficiency and heart failure [2] - Meizhong Jiahe intends to raise approximately 270 million HKD through a share placement, focusing on hospital construction, medical AI, and operational funding [3] Group 2 - ST Weiming has successfully recovered 100% equity of Xiamen Weiming, resolving long-standing equity disputes and stabilizing corporate governance [4] - Guangji Pharmaceutical has been fined 1.5 million yuan for information disclosure violations, highlighting governance issues and the need for compliance to restore investor confidence [5]

药品名称：腺苷钴胺胶囊 剂型：胶囊剂 证券代码：600479 证券简称：千金药业 公告编号：2025-039 株洲千金药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，株洲千金药业股份有限公司（以下简称"公司"）下属子公司湖南千 金湘江药业股份有限公司（以下简称"千金湘江药业"）收到国家药品监督管理 局核准签发的腺苷钴胺胶囊（0.5mg）《药品注册证书》（证书编号：2025S02155）， 公司下属子公司湖南千金协力药业有限公司（以下简称"千金协力药业"）收到 国家药品监督管理局核准签发的沙库巴曲缬沙坦钠片（100mg）《药品注册证书》 （证书编号：2025S02192）。现将相关情况公告如下： 一、药品基本信息 （一）腺苷钴胺胶囊 规格：0.5mg 注册分类：化学药品 3 类 药品批准文号：国药准字 H20254834 药品上市许可持有人：湖南千金湘江药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册， ...

Group 1 - The stock price of Qianjin Pharmaceutical (600479) closed at 10.93 yuan on July 18, 2025, with a slight increase of 0.18% and a turnover rate of 1.83% [1] - The trading volume was 76,700 shares, with a total transaction amount of 83.58 million yuan [1] Group 2 - On July 18, 2025, the net outflow of main funds for Qianjin Pharmaceutical was 925,800 yuan, accounting for 1.11% of the total transaction amount [2][4] - The net outflow of speculative funds was 3.86 million yuan, representing 4.62% of the total transaction amount, while retail investors had a net inflow of 4.79 million yuan, making up 5.73% of the total transaction amount [2][4] Group 3 - Qianjin Pharmaceutical announced its 2024 annual equity distribution plan, stating a cash dividend of 0.36 yuan per share [2][4] - The record date for shareholders is July 24, 2025, and the ex-dividend date and cash dividend payment date are both set for July 25, 2025 [2][4] - The total cash dividend distribution amounts to 150,662,562.12 yuan [2]

株洲千金药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.36元 一、 通过分配方案的股东大会届次和日期 证券代码：600479 证券简称：千金药业 公告编号：2025-038 本次利润分配方案经公司2025 年 5 月 29 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本418,507,117股为基数，每股派发现金红利0.36 元（含税） ，共计派发现金红利150,662,562.12元。 三、 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/24 | － | 2025/7/25 | 2025/7/25 | | 四 ...

2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 证券代码：600479 证券简称：千金药业 公告编号：2025-038 株洲千金药业股份有限公司 A 股每股现金红利0.36元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/24 | － | 2025/7/25 | 2025/7/25 | 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本418,507,117股为基数，每股派发现金红利0.36 元（含税），共计派发现金红利150,662,562.12元。 1. 发放年度：2024年年度 2. 分派对象： 三、 相关日期 差异化分红送转： 否 一、 通过分配方案的股东 ...

Core Insights - The first aid kit industry is experiencing significant growth due to increased safety awareness and the need for emergency preparedness in various settings such as schools, businesses, and homes [1][11] - The market size of China's first aid kit industry is projected to reach 708 million yuan in 2024, reflecting a year-on-year increase of 4.94% [1][11] - Government policies promoting safety and health have created a favorable environment for the first aid kit industry, making it an essential part of urban and rural development [1][11] Industry Overview - First aid kits are containers that store medical supplies and medications for initial emergency treatment before professional medical help arrives [3] - Different types of first aid kits serve various purposes, including outdoor, disaster, medical, and civilian kits, containing items like oxygen tanks, splints, blood pressure monitors, and dressings [3][7] Market Demand - The demand for first aid kits is increasing due to urbanization and faster-paced lifestyles, leading to a greater need for emergency response to minor injuries and health issues [1][11] - The household first aid kit market is also expanding, with its size projected to grow from 277 million yuan in 2016 to 425 million yuan in 2024, representing a compound annual growth rate of 5.50% [13] Competitive Landscape - The first aid kit industry is becoming more concentrated, with leading companies gaining advantages in market share, technological capabilities, and brand influence [15] - Key players in the industry include Blue Sail Medical, Jiangsu Southern Medicine, and Yunnan Baiyao, among others [15][16][18] Sales Channels - E-commerce platforms are increasingly important for first aid kit sales, benefiting from changing consumer shopping habits and the rapid development of online markets [9] - In 2024, China's e-commerce transaction volume is expected to reach 46.41 trillion yuan, marking a year-on-year increase of 3.90% [9] Future Trends - The market demand for first aid kits is expected to grow due to improvements in the medical emergency system, heightened public health awareness, and the frequency of various emergencies [20] - Future first aid kits may incorporate technologies like IoT and big data for remote monitoring and smart diagnostics, with personalized kits designed for specific demographics such as children and the elderly [20]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Zhuzhou Qianjin Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the repurchase and cancellation of certain restricted stocks under its 2021 incentive plan, in compliance with relevant laws and regulations [2][11][14] Group 1: Approval and Authorization - The company has completed the necessary procedures for the repurchase and cancellation of restricted stocks as part of its incentive plan [4][11] - The independent directors have expressed their agreement with the relevant proposals regarding the incentive plan [5][9] - The company has received approval from the Zhuzhou Municipal Government's State-owned Assets Supervision and Administration Commission for the implementation of the incentive plan [6][11] Group 2: Repurchase and Cancellation Details - The repurchase and cancellation are due to the failure to meet performance assessment requirements, specifically a revenue growth rate of at least 50% for the second release period and 75% for the third release period compared to 2020 [11][12][13] - A total of 5,490,000 shares will be repurchased and canceled, involving 121 individuals [12][13][14] - The repurchase is expected to be completed by July 10, 2025, with necessary filings to be made with the relevant authorities [13][14] Group 3: Compliance and Legal Opinion - The legal opinion asserts that the reasons, quantities, and arrangements for the repurchase and cancellation comply with the relevant management measures and regulations [11][14] - The company is required to fulfill its information disclosure obligations and handle the reduction of registered capital [14]

证券代码：600479 证券简称：千金药业 公告编号：2025-037 。根据公司 2021 年第一次临时股东大 会的授权，相关事项无需再提交股东大会审议。具体内容详见公司于 限制性股票激励计划第二个及第三个解除限售期解除限售条件未成 就暨回购注销相关限制性股票的公告》 （公告编号：2025-026） 关于 2021 年限制性股票激励计划第二个及第三个解除限售期解除限 售条件未成就暨回购注销相关限制性股票通知债权人的公告》（公告 编号：2025-027），至今公示期已满 45 天。公示期间未出现债权人申 报债权并要求公司清偿债务或者提供相应担保的情况。 株洲千金药业股份有限公司 关于限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 回购注销原因：株洲千金药业股份有限公司（以下简称"公 司" ）2021 年限制性股票激励计划第二个及第三个解除限售期解除限 售条件未成就，公司拟对所涉激励对象已获授但尚未解除限售的 ? 本次回购注销股份的有关情况 回购股份数（股） 注销股份数（股） 注销 ...